SITE010-0279

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE010 (ESP) (Dr. Silva) · consented 2023-01-23

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 70); relationship: Y

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-24 (study day 317); relationship: Y

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: UNKNOWN; onset 2024-01-17 (study day 341); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-25 (study day 349); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-10 (study day 365); relationship: N

severe serious assessed 2026-08-18

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-04-25 (study day 440); relationship: not assessed; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-04-27 (study day 442); relationship: Y

severe assessed 2026-08-18

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-04-29 (study day 444); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.